Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 13;40(10):995–1005. doi: 10.1007/s11604-022-01323-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022, corrected publication 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 A — 55-year-old female with multiple pulmonary and pleural oligometastases from uterine body cancer. This patient had repeatedly undergone resection for pulmonary metachronous oligometastatic disease (OMD), but three pulmonary and pleural metastases rapidly recurred after resection resulting in a diagnosis of repeated OMD. a Before SBRT. b Dose distribution: 56 Gy in 4 fractions, D95% prescription, 80% isodose (BED₁₀ = 134.4 Gy, BED_10max = 192.5 Gy). c 12 months after SBRT: Post-irradiation change (Grade 1 radiation pneumonitis). Diagnosed as local control. d FDG-PET before SBRT: Accumulation at two pulmonary and pleural oligometastases (red arrow). e FDG-PET at 7 months after SBRT: Although the three irradiated lesions were controlled locally (red arrow), multiple metastases at axillary lymph node, skin and lungs were observed at the same time 7 months after the completion of SBRT (blue arrow)